Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (8978)	8/24/2003 10:18:37 AM
From: tom pope	of 52153

This is from that article, apt in view of the immediately preceding discussion on biogenerics. One angel not fearing to tread? A: We've been accumulating Stada Arzneimittel, which is the largest generic drug company in Europe. Generics really haven't gotten a big play in Europe like they have in the U.S. So Stada is selling at a severe discount to the U.S. generic drug companies, while it is growing faster than the U.S. companies. But what has gotten us very excited about it is that they are making a foray into bio-generics as well. They have a manufacturing plant that they bought years ago that has been FDA-licensed. And they are developing erythropoeitin, alpha- and beta-interferon and the growth factor GCSF -- for their patent expirations in the second half of the decade.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next